Bevacizumab and Bortezomib in Patients With Advanced Malignancy

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT00428545
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
N/A - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab — DRUG
    Starting Dose 2.5 mg/kg By Vein On Day 1 Every 21 Days
  • Bortezomib — DRUG
    Starting Dose 0.7 mg/m\^2 By Vein On Days 1 and 8 Every 21 Days

Study Details

The goal of this clinical research study is to find the highest tolerable dose of Avastin™ (bevacizumab) and Velcade™ (bortezomib) that can be given in combination to patients with a metastatic or unresectable advanced malignancy. The safety and effectiveness of this drug combination will also be studied.

Key Dates

First listed
Jan 30, 2007
Start date
Jan 31, 2007
Status verified
Feb 2013
Primary completion
Nov 30, 2012
Completion
Nov 30, 2012

Study Design

Enrollment
104 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Bevacizumab + Bortezomib
    Bevacizumab starting Dose 2.5 mg/kg By Vein On Day 1 Every 21 Days. Bortezomib starting Dose 0.7 mg/m\^2 By Vein On Days 1 and 8 Every 21 Days.

Primary Outcome Measure

Maximum tolerated dose (MTD) and Dose-limiting toxicities (DLT) of Combination Treatment with Bevacizumab and Bortezomib [ Time Frame: Weekly during 21 Day Cycle ]

Locations (1)

FacilityCityStateZIPSite coordinators
UT MD Anderson Cancer CenterHoustonTexas77030-

Find similar trials in Houston, TX

By condition
Multiple myeloma
By specialty
OncologyBlood cancer
By research site
UT MD Anderson Cancer Center· Houston, TX

Related Studies